3556 results for «218»
3556 results
DCB after REC-CAGEFREE 1 - Vulnerable plaque PCI after PREVENT
21 May 2025 – From EuroPCR 2025
Reflect on the impact of recent trials REC-CAGEFREE 1 and PREVENT on the use of drug-coated balloons (DCB) and preventive PCI for vulnerable plaque. This session includes case discussions highlighting DCB applications and insights from cutting-edge clinical studies.
Multi-modality assessment of coronary disease
21 May 2025 – From EuroPCR 2025
This session offers comprehensive multi-modality assessment of coronary disease, integrating advanced imaging and functional testing. Topics include diagnostic yield of OCT and cardiac MRI for MINOCA, transitioning coronary plaque vulnerability assessment from invasive to non-invasive methods, relationships between QFR and IVUS post-PCI in complex lesions, combined...
ACS with normal coronary arteries: angiography done, job done?
21 May 2025 – From EuroPCR 2025
Understand the clinical significance of MINOCA and learn diagnostic strategies integrating invasive and non-invasive tests to identify underlying etiologies. This session provides therapeutic insights tailored to specific MINOCA endotypes through illustrative cases.
New tools for left main treatment
21 May 2025 – From EuroPCR 2025
Examine new tools and strategies tailored for left main coronary artery treatment. This session covers real-world data on intracoronary imaging guidance, post-PCI FFR assessment following provisional T stenting, safety and efficacy of intravascular lithotripsy for calcified left main disease, drug-coated balloon (DCB) treatments for true bifurcation...
Optimising CTO outcomes by lesion selection
21 May 2025 – From EuroPCR 2025
Optimize chronic total occlusion (CTO) PCI outcomes through lesion selection strategies. This session reviews coronary calcium patterns via CT, target vessel considerations, distal vessel remodeling, imaging-guided versus conventional approaches, and complex lesion cases.
TAVI: contemporary practice
21 May 2025 – From EuroPCR 2025
Stay updated on contemporary TAVI practices with insights from the 2024 European TAVI PATHWAY Registry. This session addresses comprehensive risk stratification in moderate aortic stenosis, safety and efficacy of repeat TAVI procedures, comparative outcomes of explant versus redo-TAVI after valve failure, and long-term neurological outcomes following...
Hotline TAVI 2: outcomes with new and established devices
21 May 2025 – From EuroPCR 2025
Review outcomes of new and established TAVI devices through pooled analyses and multicenter studies. Topics include comparisons of balloon-expandable valves, intra- versus supra-annular self-expanding valves, and insights from the ACURATE IDE and ACURATE prime studies.
Intracoronary imaging for complex PCI: a must!
21 May 2025 – From EuroPCR 2025
Recognize the indispensable role of intracoronary imaging in managing complex PCI cases. This session explores the evolution of multivessel NSTEMI treatment using DES, BRS, DCB, and imaging, challenges with recurrent in-stent restenosis across multiple stent layers, innovative imaging solutions for complex lesions, and diagnostic approaches to...
Management of stent-related complications
21 May 2025 – From EuroPCR 2025
This session addresses the management of stent-related complications through a series of dramatic clinical cases. Learn methodical approaches to routine and crisis scenarios including primary PCI complications, failure to stent, and unexpected challenges encountered during interventions, highlighting practical bailout techniques and decision-making frameworks.
How to select appropriate cardiovascular intervention for a patient with tricuspid regurgitation?
21 May 2025 – From EuroPCR 2025
Learn how to select appropriate cardiovascular interventions for tricuspid regurgitation patients by considering comorbidities, anatomical factors influencing procedural success, and imaging criteria for device selection. The session includes patient vignettes to illustrate decision-making pathways.
DCB in de novo lesions: new valid option?
20 May 2025 – From EuroPCR 2025
Explore the emerging role of drug-coated balloons (DCB) in treating de novo coronary lesions. This session discusses complexity management, comparisons with drug-eluting stents (DES), and the potential of DCBs as valuable alternatives, especially in high bleeding risk patients.
Myval Octapro THV - Optimise patient outcomes with novel design, data and daily clinical practice
21 May 2025 – From EuroPCR 2025
This session presents the latest updates on the novel Myval Octapro transcatheter heart valve (THV), based on one year of real-world clinical experience. Experts share practical tips and clinical cases that highlight how this innovative device can improve TAVI patient outcomes. The session also addresses imaging and...
Clinical outcomes of left main PCI
21 May 2025 – From EuroPCR 2025
This session reviews clinical outcomes of left main PCI in various contexts including ACS, complex lesion risk stratification with BCIS-CHIP score, and spontaneous coronary artery dissection. It also compares double-stent techniques and examines five-year results to guide clinical decision-making.
A new percutaneous technique for effective vascular access site closure in patients undergoing TAVI and thoraco-abdominal aortic aneurysm repairs
09 Jan 2019
Results of the PASTE study
Authors :
PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB: After revascularization of culprit lesions, assessment of coronary plaque size and composition matter!
17 Oct 2020
PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB trials were presented at TCT Connect 2020. Hector Garcia-Garcia provides a summary of the key messages.
Author
The AQUATIC trial: Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation
01 Sep 2025
Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.
Author
![The AQUATIC trial [Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial]](https://www.pcronline.com/var/pcrov3/storage/images/pcronline/news/whats-new-on-pcronline/2025/esc/aquatic-trial-quitting-versus-using-aspirin-therapy-patients-stabilized-cad-stenting-long-term-oral-anticoagulation/27448089-9-eng-GB/The-AQUATIC-trial-Assessment-of-quitting-versus-using-aspirin-therapy-in-patients-with-stabilized-coronary-artery-disease-after-stenting-who-requi_image_responsive_6.jpg)